Last reviewed · How we verify
NCT04074629: Nano-Skin-MS
Novel Nanosensor Array for Detection of Volatile Biomarkers From Skin in Multiple Sclerosis
NA trial testing Diagnosis, skin volatile organic compounds (VOCs) in Multiple Sclerosis in 107 participants. Completed in 2 August 2022.
23 May 2022
Quick facts
| Lead sponsor | Carmel Medical Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 107 |
| Start date | 16 December 2019 |
| Primary completion | 23 May 2022 |
| Estimated completion | 2 August 2022 |
| Sites | 1 location across Israel |
Drugs / interventions tested
- Diagnosis, skin volatile organic compounds (VOCs)
Conditions studied
- Multiple Sclerosis — all drugs for Multiple Sclerosis →
Sponsor
Carmel Medical Center
Who can join
Adults 18 to 75, any sex, with Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Multiple Sclerosis (MS) is the most common chronic neurological disease affecting young adults, with onset usually at the age 20-40 years. The disease is characterized by two main phenotypes: Relapse-Remitting MS (RR-MS) and Primary Progressive MS (PP-MS). RR-MS is the most common type of disease, for long-term management of the disease patients are treated with immunomodulatory drugs (IMD) which reduce disease activity. Response to therapy varies among patients. Presently there are no biomarkers available for diagnosis and routine follow-up of MS. Many MS patients suffer from unexpected relapsing episodes that influence dramatically their mental and physical conditions, with high stress levels, tremors, motoric disabilities, blindness and more. Therefore, early target treatment in relapse episodes is crucial, yet sufficient tools for predicting and identifying early symptoms of an upcoming relapse episode are not available. The investigators have most recently shown that breath VOCs can be used to classify among MS and non-MS patients. The major aims of the current proposal is to study the plausibility of skin based VOCs as biomarkers for MS diagnosis and To Identify and characterize skin-based VOCs as biomarkers of the clinical relapse and disease activity.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Nanotechnology in inflammation: cutting-edge advances in diagnostics, therapeutics and theranostics.
Liu Y, Lin Z, Wang Y, Chen L, et al · · 2024 · cited 22× · PMID 38646646 · DOI 10.7150/thno.91394
Verify or expand the search:
- PubMed search for NCT04074629
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Multiple Sclerosis
Currently open trials in the same condition.
- NCT07507084 — The Effect of Internal- or External-Focused Exercise Training, Administered in Conjunction With a Cognitive Task, on Wal · NA · recruiting
- NCT07524231 — Evaluation of the Effects of Laughter Yoga · NA · recruiting
- NCT07489794 — URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSIS · recruiting
- NCT07236684 — Identification of Factors Related to UI in Patients With MS and EMG Assessment of PFM Activity · recruiting
- NCT07500727 — Skeletal Muscle Aging and Responsiveness in Aged People With MS · NA · recruiting
Other Carmel Medical Center trials
Trials by the same sponsor.
- NCT06604455 — Impact of Acupuncture and Integrative Medicine on Patients Quality-of-life During National Emergency and Wartime · NA · recruiting
- NCT06612749 — Assessing the Impact of Integrative Medicine on Anxiety and Wellbeing of Healthcare Providers Exposed to Terror or War · NA · recruiting
- NCT06598020 — Evaluating the Impact of an Integrative Oncology Training Program for Healthcare Providers · NA · active not recruiting
- NCT06590766 — Impact of Acupuncture and Manual Therapies on Patients' Quality-of-life in a Hospital-to-community Continuum · NA · recruiting
- NCT06167057 — POST URS Chemotherapy Instillation · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04074629 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Carmel Medical Center
- Last refreshed: 7 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04074629.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing